Get the Stockscreener App
20.40
0.00%
0.00
After Hours:
20.43
0.03
+0.15%
Bausch Lomb Corp stock is traded at $20.40, with a volume of 3.43M.
It is up +0.00% in the last 24 hours and up +19.02% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$20.40
Open:
$20.885
24h Volume:
3.43M
Relative Volume:
3.10
Market Cap:
$7.29B
Revenue:
$5.21B
Net Income/Loss:
$-211.00M
P/E Ratio:
-33.02
EPS:
-0.6179
Net Cash Flow:
$861.30K
1W Performance:
+17.04%
1M Performance:
+19.02%
6M Performance:
+32.99%
1Y Performance:
+31.87%
1-Day Range:
$20.27
$21.36
1-Week Range:
$17.30
$21.36
52-Week Range:
$14.44
$21.36
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, RMD, ALC, WST
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
20.40 | 7.29B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
448.76 | 158.54B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
198.34 | 54.03B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
252.83 | 35.56B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
71.13 | 34.38B | 10.63B | 819.00M | 1.59B | 1.6577 |
WST
West Pharmaceutical Services Inc
|
416.67 | 29.32B | 3.22B | 542.70M | 458.00M | 7.4805 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-26 | Initiated | Barclays | Overweight |
| Sep-09-26 | Initiated | Leerink Partners | Outperform |
| Jul-28-26 | Initiated | UBS | Buy |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
RBC Raises Price Target on Bausch + Lomb to $23 From $21, Keeps Outperform Rating - marketscreener.com
More than 80% of people surveyed with dry eye changed their habits - Stock Titan
Bausch + Lomb Corporation 2026 Q3ResultsEarnings Call Presentation (NYSE:BLCO) 2026-10-29 - Seeking Alpha
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call - Yahoo Finance
Bausch + Lomb Posts Strong Third Quarter Results, Raises Full-Year Guidance - VisionMonday.com
Bausch + Lomb Corporation Stock 12‑Month Price Target Raised to $19.92, Implies 13% Upside - TradingView
Revenue hits $1.38B as Bausch + Lomb (BLCO) turns last year's $28M quarterly loss into a profit. - Stock Titan
Bausch + Lomb Corporation (BLCO) Stock Forecasts - Yahoo Finance
Bausch + Lomb: Q3 Earnings Snapshot - Yahoo Finance
Bausch + Lomb Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - marketscreener.com
Bausch + Lomb Corporation Q3 2026 Earnings Call Summary - Yahoo Finance
Bausch + Lomb Posts A Third Beat-And-Raise On Margin Expansion, But An Abrupt CEO Change Clouds The Story - Finviz
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
Earnings Flash (BLCO) Bausch + Lomb Corporation Reports Q3 Revenue $1.38B, vs. FactSet Est of $1.37B - www.marketscreener.com
Bausch + Lomb Corporation (BLCO) Tops Q3 EPS by 13c; offers guidance - StreetInsider
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance - Yahoo Finance
Bausch + Lomb (BLCO) reports Q3: everything you need to know ahead of earnings - Yahoo Finance
Bausch + Lomb Corporation Estimates – NYSE:BLCO - TradingView
Earnings Preview: BLCO to Report Financial Results Pre-market on October 28 - Moomoo
Bausch + Lomb Announces Board of Directors Update - Medical Product Outsourcing
Enterprise value to revenue forward of Bausch + Lomb Corporation – DUS:S2L - TradingView
MarketBeat cites USD 19.46 target for Bausch + Lomb stock - ad-hoc-news.de
Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up - Benzinga
Bausch + Lomb Corporation (BLCO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bausch + Lomb Corp. (S2L.SG) Q2 FY2026 earnings call transcript - Yahoo Finance
Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation - Glance by Eyes On Eyecare
Bausch + Lomb Corporation Announces Cessation of Brent Saunders as Director, Effective October 12, 2026 - marketscreener.com
Bausch + Lomb Corporation (BLCO) Stock Forecasts - Yahoo Finance
Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief - Reuters
Thomas J. Appio Named Interim CEO of Bausch + Lomb as Brent Saunders Departs - VisionMonday.com
What Could Bausch Health (TSX:BHC) Reveal in Its Next Results? - Kalkine Media
Bausch + Lomb names Appio interim CEO as Saunders departs - StreetInsider
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance - Yahoo Finance
Bausch Health's CEO now also leads Bausch + Lomb as interim CEO. - Stock Titan
Bausch + Lomb Corporation and Bausch Health Companies Inc. Announce CEO Changes - www.marketscreener.com
Why Is Bausch + Lomb Stock Falling Monday?Bausch Health Companies (NYSE:BHC), Bausch & Lomb (NYSE:BLCO - Benzinga
Bausch + Lomb CEO Brent Saunders departs, for a second time - FirstWord Pharma
Barclays Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24 - Moomoo
RBC Capital Remains a Buy on Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Bausch + Lomb's Dry Eye Disease Prescription Momentum Builds, Forex Turns as Modest Headwind in Q3, RBC Says - marketscreener.com
Barclays Reaffirms Their Buy Rating on Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Bausch & Lomb Initiated at Overweight by Barclays - Moomoo
Bausch + Lomb stock gets BL1243 update after FDA meeting - AD HOC NEWS
Why Is SeeLyra Approval Important For Bausch + Lomb (TSX:BLCO)? - Kalkine Media
Bausch + Lomb to Advance Eye Disease Treatment Following FDA Meeting - marketscreener.com
A possible medicine to take by mouth for macular degeneration is planned for 2027 testing - Stock Titan
Bausch + Lomb Sets Date for Third-Quarter 2026 Earnings Release and Investor Call - The Globe and Mail
Bausch + Lomb Corporation (TSX:BLCO): Can Vision Care Grow? - Kalkine Media
Bausch + Lomb Corporation - Baystreet.ca
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bausch Lomb Corp Stock (BLCO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ling Karen | Former Director |
Sep 28 '26 |
Proposed Sale |
16.83 |
4,500 |
75,735 |
0 |
| Munsch Frederick | SVP, Controller and CAO |
Aug 10 '26 |
Sale |
16.78 |
52,900 |
887,662 |
45,831 |
| Munsch Frederick | Former Officer |
Aug 10 '26 |
Proposed Sale |
16.78 |
52,900 |
887,885 |
0 |
| VON ESCHENBACH ANDREW C. | Former Director |
Aug 07 '26 |
Proposed Sale |
16.58 |
6,059 |
100,430 |
0 |
| VON ESCHENBACH ANDREW C. | Director |
Aug 07 '26 |
Sale |
16.58 |
6,059 |
100,458 |
63,733 |
| VON ESCHENBACH ANDREW C. | Director |
Aug 06 '26 |
Sale |
16.50 |
12,500 |
206,250 |
69,792 |
| VON ESCHENBACH ANDREW C. | Former Director |
Aug 06 '26 |
Proposed Sale |
16.50 |
12,500 |
206,193 |
0 |
| SAUNDERS BRENT L | CEO and Chairman of the Board |
Mar 06 '26 |
Buy |
17.14 |
14,700 |
251,958 |
966,575 |
| Eldessouky Sam | EVP and CFO |
Mar 06 '26 |
Buy |
17.13 |
4,000 |
68,520 |
403,130 |
| Bailey A Robert D | EVP & Chief Legal Officer |
Mar 06 '26 |
Buy |
17.15 |
14,600 |
250,332 |
231,890 |
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):